Cognition Therapeutics Stock Market Outlook
| CGTX Stock | USD 1.24 0.01 0.81% |
This sentiment view is most useful when read alongside valuation, volatility, and analyst coverage for the stock, not in isolation. Around 51% of recent sentiment around Cognition Therapeutics has been mildly constructive over the recent sample. Taken on its own, that leaves the current sentiment reading for Cognition Therapeutics close to neutral at this time.
Investor Comfort Level
PanicConfidence
51 · Impartial
Elasticity to Hype and News Sentiment
Cognition Therapeutics news sentiment reading of 50% (mixed) tracks how media and analyst commentary are framing the investment case. Cross-checking that reading with earnings momentum and price action helps confirm whether the narrative is running ahead of or behind the business.
Given a 90-day horizon, with a moderate risk tolerance, the model output for Cognition Therapeutics is 'Hold'. The buy or sell signal for Cognition Therapeutics reflects the output of quantitative models evaluating price history. Risk modeling is used to produce a recommendation aligned with the investor's portfolio objectives. The automated directive reflects a statistical assessment based on historical performance and current conditions.
Cognition |
Run Cognition Therapeutics Outlook Model
This Cognition model signal serves as a cross-check against the prevailing consensus on Cognition Therapeutics. Macroaxis does not hold any position in Cognition Therapeutics or other equities on which advice is provided. Risk tolerance and time horizon parameters shape the Cognition Therapeutics' model output.
How This Model Works
The recommendation output for Cognition Therapeutics is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an average risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Hold
Market Performance | Contained | Details | |
Volatility | Abnormal | Details | |
Current Valuation | Above Model Estimate | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Cognition Therapeutics' current outlook reflects mixed signals, where recent market performance has undercut momentum. The model's 'Hold' signal reflects mixed signals where neither bullish nor bearish factors dominate. A Hold indicates that neither bullish nor bearish factors dominate across the model inputs, producing a balanced but inconclusive reading. For the selected horizon, Cognition Therapeutics yields Risk Adjusted Performance of 0.0886, Jensen Alpha of 0.5741, and Total Risk Alpha of 0.5369, which produce a balanced but non-directional signal.The model output for Cognition Therapeutics integrates risk-adjusted performance, valuation signals, and the current analyst outlook into a single quantitative reading. For additional context on this micro-cap stock, evaluate the full set of Cognition Therapeutics reported fundamentals, including number of employees, net asset, as well as the relationship between the current ratio ttm and ebitda ttm. Given Cognition Therapeutics' number of shares shorted reading, its fundamentals and Probability Of Bankruptcy provide additional context for this model output.
Recent Events and Market Context
The events below reflect recent headlines associated with Cognition Therapeutics. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Current Analysts Advice
The current analyst picture for Cognition Therapeutics reflects a rolling average of published recommendations from research firms, banks, and independent analysts. The main value is context: it reveals whether professional opinion is becoming more constructive, more cautious, or simply more dispersed.
Target-price estimates for Cognition Therapeutics summarize external analyst assumptions, which means they may diverge from the platform's own recommendation framework. That is why the consensus view merits review together with fundamentals, technical context, and current risk tolerance.
Returns Distribution Density
The spread of Cognition Therapeutics' past returns sets a baseline for realistic forward assumptions. For Cognition Therapeutics, the peak of the curve marks the most common outcome, while the tails show rare extremes. Value At Risk and Upside Potential measure both sides of that spread for Cognition Therapeutics.
| Mean Return | 0.62 | Value At Risk | -6.25 | Potential Upside | 10.26 | Standard Deviation | 7.53 |
Return Density |
| Distribution |
How often does Cognition Therapeutics make a large move up or down? The distribution of Cognition Therapeutics's past returns shows how rare those extremes really are. This supports comparison of different risk-return profiles on a risk-reward basis.
Key Drivers of Volatility and Market Exposure
Systematic exposure aligns Cognition Therapeutics with broad stock market volatility, while unsystematic drivers reflect company or sector-specific developments. Latest disclosures for Cognition Therapeutics show a Downside Deviation of 8.14, a Mean Deviation of 4.91, and a Semi Deviation of 7.18.
α | Alpha over Dow Jones | 0.57 | |
β | Beta against Dow Jones | 4.06 | |
σ | Overall volatility | 7.56 | |
Ir | Information ratio | 0.08 |
Fundamentals Vs Peers
Cognition Therapeutics' margins, returns, and leverage ratios take on meaning when measured against companies in a similar operating model. Cognition Therapeutics' key financial ratios are tested against industry norms - deviations in either direction carry analytical signal. Consistent outperformance on key metrics relative to peers strengthens the fundamental case for Cognition Therapeutics.
| Better Than Average | Worse Than Average | Compare Cognition Therapeutics to competition |
| Fundamentals | Cognition Therapeutics | Peer Average |
| Return On Equity TTM | -0.89 | -0.31 |
| Return On Asset TTM | -0.76 | -0.14 |
| Current Valuation | 77.75 M | 16.62 billion |
| Shares Outstanding | 89.35 M | 571.82 million |
| Shares Owned By Insiders | 2.26 % | 10.09 % |
| Shares Owned By Institutions | 23.69 % | 39.21 % |
| Number Of Shares Shorted | 7.32 M | 4.71 million |
| Price To Book TTM | 3.34 X | 9.51 X |
| EBITDA TTM | -47.8 M | 3.9 billion |
| Net Income TTM | -23.49 M | 570.98 million |
| Cash And Equivalents TTM | 46.61 M | 2.7 billion |
| Cash Per Share TTM | 1.94 X | 5.01 X |
| Total Debt TTM | 638 K | 5.32 billion |
| Debt To Equity TTM | 0.02 % | 48.70 % |
| Current Ratio TTM | 4.20 X | 2.16 X |
| Book Value Per Share TTM | 0.39 X | 1,931 |
| Cash Flow From Operations TTM | -24.59 M | 971.22 million |
| Short Ratio TTM | 4.84 X | 4.00 X |
| Earnings Per Share | -0.32 X | 3.12 X |
| Target Price | 3.5 | N/A |
| Number Of Employees | 14 | 18,840 |
| Trailing Beta | 1.81 | -0.15 |
| Market Capitalization TTM | 114.37 M | 19.03 billion |
| Total Asset TTM | 48.39 M | 29.47 billion |
| Retained Earnings TTM | -198.65 M | 9.33 billion |
| Working Capital TTM | 34.07 M | 1.48 billion |
| Net Asset | 48.39 M | N/A |
Note: Acquisition by Richstone Ellen B of 10000 shares of Cognition Therapeutics at 2.655 subject to Rule 16 b-3 [view details]
Market Momentum
Cognition Therapeutics neutral RSI of 55 combined with high-beta sensitivity (4.0581) reveals whether current momentum is driven by company-specific demand or market-wide flows. That elevated sensitivity means momentum signals carry amplified risk on reversals.
Recommendation Framework, Assumptions & Editorial Oversight
The model output for Cognition Therapeutics reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for Cognition Therapeutics include ROE of -88.6%, market cap of 114.37 million. 
Cognition Therapeutics data is compiled from periodic company reporting and market reference feeds and standardized for comparability. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Junior Member of Macroaxis Editorial Board
Finance background: Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.